Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Patent Litigation
-
By Kevin E. Noonan — The patent blogging team of John White and Eugene Quinn will be doing their part to keep the rest of us informed about the progress of the temporary restraining order/preliminary injunction hearing to be held on Wednesday in GlaxoSmithKline’s lawsuit against Jon Dudas and the U.S. Patent and…
-
By Kevin E. Noonan — Amgen’s recombinant erythropoietin (EPO) franchise (Aranesp® and Epogen®, as well as Johnson & Johnson’s Procrit®) survived another challenge last week, when a jury found that Hoffmann-LaRoche’s pegylated EPO preparation (Mircera®) infringed three Amgen patents: U.S. Patent Nos. 5,547,933 (the ‘933 patent), 5,441,868 (the ‘868 patent), and 5,618,698 (the…
-
By Sherri Oslick — Late last week, Novartis and Ranbaxy filed a joint stipulation and dismissal in their pending lawsuit over generic valsartan, the active ingredient in Novartis’ Diovan®, used to treat hypertension. The suit, filed on August 9, 2007 in the District Court of New Jersey (see previous report), had been pending…
-
By Sherri Oslick — As reported here, on August 9, Eli Lilly filed suit in the District Court of New Jersey against Actavis Elizabeth in answer to Actavis’ filing of an ANDA (and concomitant Paragraph IV certification) to manufacture a generic version of Lilly’s Strattera®. Earlier this month, Lilly filed an amended complaint…
-
By Sherri Oslick — On Tuesday, Teva Pharmaceuticals and Dr. Reddy’s Laboratories filed a joint stipulation of dismissal in their pending lawsuit over generic sertraline hydrochloride (the API in Pfizer’s Zoloft®, used to treat depression). The suit, originally filed on February 1, 2007 in the District Court of New Jersey, was dismissed without…
-
By Kevin E. Noonan — Horsham, Pennsylvania biotech company Nucleonics, Inc. announced today that it has filed a petition with the Court of Appeals for the Federal Circuit for rehearing en banc of the Court’s July 20, 2007 decision upholding dismissal of its declaratory judgment counterclaims against Benetic Australia Ltd. over patents on…
-
By Donald Zuhn — Ranbaxy Laboratories Ltd. announced today (July 26, 2007) that it had reached an agreement with GlaxoSmithKline in which GlaxoSmithKline would dismiss its patent infringement suit against Ranbaxy. GlaxoSmithKline had asserted its U.S. Patent No. 4,957,924, directed to Valacyclovir Hydrochloride, against Ranbaxy, which received final approval to market a generic…
-
By Sherri Oslick — Ortho-McNeil, Inc. announced late last week that it has settled its lawsuit against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc. and Kali Laboratories, Inc., over the patent covering Ortho’s Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain). As part of the settlement agreement, Par/Kali…
-
By Donald Zuhn — On Monday, ARIAD Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Massachusetts had ruled in its favor in a patent infringement suit ARIAD filed against Eli Lilly and Co. ARIAD and co-plaintiffs Massachusetts Institute of Technology, The Whitehead Institute for Biomedical Research, and The President…
-
By Donald Zuhn — Applied Nanoscience Inc. announced today (July 6, 2007) that it has entered into a settlement agreement with NanoScale Coroporation. The agreement ends the lawsuit NanoScale filed against Applied Nanoscience, Emergency Filtration Products, Inc., Applied Nanoscience President Thomas K. Allen, and Emergency Filtration Products President and CEO Douglas K. Beplate,…
Patent Docs 